These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 3197751)
61. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Corbin DO; Wood DA; Macintyre CC; Housley E Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704 [TBL] [Abstract][Full Text] [Related]
62. Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group. Thromb Res; 1989 Jul; 55(1):13-23. PubMed ID: 2528841 [TBL] [Abstract][Full Text] [Related]
63. Ketanserin in the treatment of traumatic vasospastic disease. Larsen VH; Fabricius J; Nielsen G; Hansen KS Br Med J (Clin Res Ed); 1986 Sep; 293(6548):650-2. PubMed ID: 3092968 [TBL] [Abstract][Full Text] [Related]
64. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related]
65. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon. Rembold CM; Ayers CR Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823 [TBL] [Abstract][Full Text] [Related]
66. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon. Belch JJ; Madhok R; Shaw B; Leiberman P; Sturrock RD; Forbes CD Lancet; 1985 May; 1(8439):1180-3. PubMed ID: 2860386 [TBL] [Abstract][Full Text] [Related]
67. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. DiGiacomo RA; Kremer JM; Shah DM Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517 [TBL] [Abstract][Full Text] [Related]
68. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795 [TBL] [Abstract][Full Text] [Related]
69. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175 [TBL] [Abstract][Full Text] [Related]